ProfileGDS5678 / 1434263_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 86% 85% 84% 84% 84% 87% 87% 84% 84% 82% 86% 85% 84% 83% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.4805186
GSM967853U87-EV human glioblastoma xenograft - Control 26.4367985
GSM967854U87-EV human glioblastoma xenograft - Control 36.2852184
GSM967855U87-EV human glioblastoma xenograft - Control 46.4671984
GSM967856U87-EV human glioblastoma xenograft - Control 56.2220284
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.4096387
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.5353487
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.1642684
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.1969384
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.0438582
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.4311886
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.3691585
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.2515784
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.0936583